AbbVie Seeks US Approval for Promising New Blood Cancer Treatment

2026-10-27 biotech

Brussels, Tuesday 27 October 2026
AbbVie has filed for US regulatory approval of etentamig after Phase 3 trial data revealed an impressive 60% reduction in disease progression risk for multiple myeloma patients.

Pivotal Regulatory Filing and Mechanism of Action

On Monday, 26 October 2026, biopharmaceutical giant AbbVie formally submitted a Biologics License Application (BLA) to the United States Food and Drug Administration (FDA) for etentamig, which is also identified in developmental pipelines as ABBV-383 [1][2][3]. The therapeutic candidate represents an investigational, second-generation B-cell maturation antigen (BCMA) by CD3 T-cell engaging bispecific antibody engineered for the treatment of adult patients diagnosed with relapsed or refractory multiple myeloma [1][2][3]. Mechanistically, the molecule is designed with an optimised architecture featuring a high-affinity bivalent BCMA-binding domain alongside a low-affinity CD3 binding domain [3]. This structural framework is intended to direct host T cells specifically to plasma cancer cells while simultaneously mitigating systemic inflammatory release, supporting a convenient monthly intravenous dosing schedule following an initial single step-up dose [1][2][3].

Phase 3 CERVINO Trial Delivers Strong Clinical Efficacy

The regulatory application is underpinned by robust clinical data generated from the global, multicentre, randomised Phase 3 CERVINO study (NCT06158841), which first unveiled topline results on 3 September 2026 before detailed presentations at the International Myeloma Society (IMS) Annual Meeting in Glasgow, Scotland [1][2][3]. The trial enrolled 393 patients with triple-class exposed relapsed or refractory disease who had undergone at least two prior lines of therapy [1][2][3]. Subjects were randomised 1:1 to receive etentamig or standard available therapies (SAT), where investigators selected from regimens including carfilzomib plus dexamethasone, elotuzumab plus pomalidomide and dexamethasone, or selinexor plus bortezomib and dexamethasone [3]. In meeting its dual primary endpoints, the etentamig arm demonstrated an overall response rate (ORR) of 74.0% compared to 45.7% in the comparator arm, generating an absolute rate improvement of 28.3% [1][2][3]. Furthermore, etentamig demonstrated a statistically significant 60% reduction in the risk of disease progression or death, marking a notable milestone for patients whose disease has resisted prior multi-agent regimens [1][2][5].

Tolerability Profile and Inpatient De-escalation Advantages

From an operational and clinical management perspective, the trial’s tolerability metrics stand out as a central differentiator within the haematological oncology landscape [1][2][3]. The incidence of cytokine release syndrome (CRS) among patients receiving the single step-up dose regimen was limited to 28.3%, with all reported events restricted entirely to low-severity grade 1 or grade 2 presentations [1][2][3]. Neurological toxicities were similarly constrained, with only a single patient recording a grade 1 immune effector cell-associated neurotoxicity syndrome (ICANS) event [3]. The most frequently noted treatment-emergent adverse events (TEAEs) occurring in at least 25% of subjects receiving etentamig were CRS, hypogammaglobulinemia, neutropenia, and anaemia [1][2][3]. Grade 3 or 4 infections occurred in 27.7% of patients on etentamig versus 19.2% for SAT, whilst grade 5 infections stood at 1.5% versus 3.1% respectively [1][2][3]. Crucially for continuous outpatient delivery, TEAEs leading to treatment discontinuation were restricted to 3.6% in the etentamig arm, representing less than a third of the 14% discontinuation rate observed with standard regimens [1][2][3].

Market Impact and Oncology Portfolio Diversification

The commercialisation prospects for etentamig arrive against a landscape of substantial unmet medical need, highlighted by estimates showing that approximately 36,000 individuals were diagnosed with multiple myeloma across the United States in 2025 alone [1][2][3]. Dr Daejin Abidoye, Vice President and Therapeutic Area Head of Oncology, Solid Tumor and Hematology at AbbVie, underlined that the filing represents an advance toward delivering an efficacious therapy engineered around the logistical realities of community and clinic-level care [1][2]. As AbbVie continues to evaluate more than 35 investigational medicines across blood cancers and solid tumours, the successful transition of etentamig from late-stage development toward commercialisation strengthens the company’s core oncology pipeline alongside its established franchises in immunology, neuroscience, and medical aesthetics [1][2][4]. For regional life sciences hubs and biotech investors, the BLA marks another pivotal validation point for dual-targeting bispecific platforms capable of reducing hospital burden whilst outperforming legacy standard-of-care regimens [1][2][5].

Sources & Ecosystem Partners

Bispecific antibodies Clinical oncology